Finger pointing to JC virus: A tale two indexes

Annals of Neurology

Volumn 76, Issue 6, 2014, Pages 789-791

  Koralnik, Igor J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NATALIZUMAB; VIRUS ANTIBODY; VIRUS DNA;

ANTIBODY PRODUCTION; ASTROCYTE; BRAIN BIOPSY; CEREBROSPINAL FLUID ANALYSIS; EDITORIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JC VIRUS; OLIGODENDROGLIA; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; ANIMAL; BLOOD; CLASSIFICATION; METABOLISM; PHYSIOLOGY; VIRUS LOAD;

ANIMALS; ANTIBODIES, VIRAL; HUMANS; JC VIRUS; VIRAL LOAD;

EID: 84913583971     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24302     Document Type: Editorial

References (18)

1. Plavina T, Subramanyam M, Bloomgren G, et al. Anti-JC Virus antibody levels in serum or plasma further define risk of natalizu-mab-associated progressive multifocal leukoencephalopathy. Ann Neurol 2014;76:802-812.
2. Warnke C, von Geldern G, Markwerth P, et al. Cerebrospinal fluid JC Virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 2014;76:792-801.
3. Gheuens S, Wuthrich C, Koralnik IJ. Progressive multifocal leukoencephalopathy: why gray and white matter. Annu Rev Pathol 2013;8:189-215.
4. Agnihotri SP, Wuthrich C, Dang X, et al. A fatal case of JC virus meningitis presenting with hydrocephalus in a human immunodeficiency virus-seronegative patient. Ann Neurol 2014;76:140-147.
5. Berger JR, Aksamit AJ, Clifford DB, et al. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology 2013;80:1430-1438.
6. Padgett BL, Walker DL. Prevalence of antibodies in human sera against JC virus, an isolate from a case of progressive multifocal leukoencephalopathy. J Infect Dis 1973;127:467-470.
7. Knowles WA, Pipkin P, Andrews N, et al. Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 2003;71:115-123.
8. Viscidi RP, Rollison DE, Viscidi E, et al. Serological crossreactivities between antibodies to simian virus 40, BK virus, and JC virus assessed by virus-like-particle-based enzyme immunoassays. Clin Diagn Lab Immunol 2003;10:278-285.
9. Hamilton RS, Gravell M, Major EO. Comparison of antibody titers determined by hemagglutination inhibition and enzyme immunoassay for JC virus and BK virus. J Clin Microbiol 2000;38:105-109.
10. Viscidi RP, Khanna N, Tan CS, et al. JC virus antibody and viremia as predictors of progressive multifocal leukoencephalopathy in human immunodeficiency virus-1-infected individuals. Clin Infect Dis 2011;53:711-715.
11. Weber F, Goldmann C, Kramer M, et al. Cellular and humoral immune response in progressive multifocal leukoencephalopathy. Ann Neurol 2001;49:636-642.
12. Kardas P, Sadeghi M, Weissbach FH, et al. Inter- and intralaboratory comparison of JC polyomavirus antibody testing using two different virus-like particle (VLP)-based assays. Clin Vaccine Immunol 2014;21:1581-1588.
13. Biogen Idec. PML incidence in patients receiving Tysabri (natalizumab). Available at: https://medinfo.biogenidec.com/. Accessed November 11, 2014.
14. Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 2010;68:295-303.
15. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012;366:1870-1880.
16. Warnke C, Pawlita M, Dehmel T, et al. An assay to quantify species-specific anti-JC virus antibody levels in MS patients. Mult Scler 2013;19:1137-1144.
17. Berger JR, Houff SA, Gurwell J, et al. JC virus antibody status underestimates infection rates. Ann Neurol 2013;74:84-90.
18. Frohman EM, Monaco MC, Remington G, et al. JC virus in CD341 and CD191 cells in patients with multiple sclerosis treated with natalizumab. JAMA Neurol 2014;71:596-602. 10.1002/ana.24302